Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 679

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 679
---
 are currently no approved therapeutics for this disease, Therefore, it is expected that VXM01 can be applied to Neurofibromatosis and prove its efficacy in treating Neurofibromatosis.                            |

F-135

33. Business combinations (cont.) (2) VXM-Preclinical VAXIMM’s preclinical programs are composed of 4 different pipelines: VXM04, VXM06, VXM08 and VXM10 •VXM04 carries human mesothelin as the target antigen. Mesothelin is a protein that is overexpressed in several solid tumors. •VXM06 targets WT1. WT1 is overexpressed in several hematological malignancies and solid tumors. In preclinical studies, VXM06 has shown potent T -cellactivation against WT1 and stand -alonetherapeutic activity in models of leukemia. •VXM08 targets CEA, a human tumor -associatedantigen overexpressed in many solid tumors. In preclinical studies, VXM08 has shown potent T -cellactivation against its target antigen as well as stand -alonetherapeutic activity in models of colorectal and lung cancer. •VXM10 targets PD -L 1, an immunomodulatory antigen upregulated in many solid tumors as well as hematological malignancies. VXM10 is currently in preclinical development and has shown stand -alonetherapeutic activity in models of leukemia. 33.4 Net cashflow from acquisition for the years ended December 31, 2023 and 2022 are as follows:

| (Korean won in unit)                                    |     |                    2023 |   |
| Net cash outflow arising from acquisition of Darnatein: |     |                         |   |
| Cash consideration                                      |     |           ₩           — |   |
| Less: cash and cash equivalent balances acquired        |     |             (88,452,978 | ) |
|                                                         |     | ₩           (88,452,978 | ) |

| (Korean won in unit)                                         |     |                2022 |   |
| Net cash outflow arising from acquisition of VAXIMM and RMC: |     |                     |   |
| Cash consideration                                           |     |       ₩           — |   |
| Less: cash and cash equivalent balances acquired             |     |      (2,249,584,807 | ) |
|                                                              |     | ₩    (2,249